Residents living with chronic obstructive pulmonary disease (COPD) are being encouraged to explore opportunities to take part in clinical research that could help shape future treatments.
The Medicines Evaluation Unit (MEU), based in Wythenshawe, is currently looking to hear from people diagnosed with COPD who may be interested in participating in upcoming clinical research studies.
COPD, or chronic obstructive pulmonary disease, is an umbrella term for a group of progressive lung conditions that cause breathing difficulties, most notably chronic bronchitis, and emphysema. It affects millions of people across the UK and can have a significant impact on everyday life.
Clinical research plays an important role in helping to develop new medicines and improve treatment options for people living with long term conditions. Participants in research studies help provide valuable information that contributes to future healthcare advances.
“There have been great advances in recent years in the development of new medicines to treat people living with COPD. We want to continue this and need volunteers to help study the effects of new treatments.” – Professor Dave Singh, Medical Director of the Medicines Evaluation Unit
Those who choose to participate will receive expert medical care throughout the study and may be compensated up to £3,000 for their time and travel expenses, depending on the study.
The Medicines Evaluation Unit has been conducting clinical research for more than 25 years and works with participants from across Greater Manchester and the surrounding areas.
Individuals interested in finding out more about COPD research opportunities can register their interest by visiting www.rewardingresearch.co.uk or by calling 0161 946 4059.
About the Medicines Evaluation Unit (MEU), an IQVIA business
Based in Wythenshawe, Manchester and founded in 1999, the Medicines Evaluation Unit, an IQVIA business, is one of the UK’s leading specialist clinical research facilities and has over 25 years’ experience of undertaking clinical trials to aid the development of ground-breaking medicines for patients and future generations.